Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Profile Name||PIK3CA wild-type|
|Gene Variant Detail|
|Relevant Treatment Approaches|
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|PIK3CA wild-type||breast cancer||predicted - sensitive||A-1210477 + WEHI-539||Preclinical - Cell culture||Actionable||In a preclinical study, combination of WEHI-539 and A-1210477 resulted in enhanced apoptosis in PIK3CA wild-type breast cancer cell lines in culture (PMID: 27974663).||27974663|
|PIK3CA wild-type||triple-receptor negative breast cancer||no benefit||Palbociclib + Pictilisib||Preclinical||Actionable||In a preclinical study, the combination of Ibrance (palbociclib) and Pictilisib (GDC-0941) did not improve growth inhibition compared to single drug treatment in PIK3CA wild-type, triple-receptor negative breast cancer cell lines in culture (PMID: 27020857).||27020857|
|PIK3CA wild-type||Her2-receptor negative breast cancer||no benefit||Alpelisib||Phase I||Actionable||In a Phase I trial, Alpelisib (BYL719) treatment resulted in no clinical benefit in 4 patients with ER-positive, ERBB2 (HER2)-negative breast cancer harboring PIK3CA mutations (PMID: 29401002; NCT01219699).||29401002|
|PIK3CA wild-type||Advanced Solid Tumor||sensitive||PX-866||Phase I||Actionable||In a Phase I study, PX-866 demonstrated efficacy and was well tolerated in patients with advanced solid tumor with both PIK3CA wild-type and mutant status (PMID: 22693357).||22693357|
|PIK3CA wild-type||Her2-receptor positive breast cancer||sensitive||Lapatinib + Paclitaxel + Trastuzumab||Phase II||Actionable||In a Phase II trial, the combination of Taxol (paclitaxel) plus Herceptin (trastuzumab) and Tykerb (lapatinib) resulted in a higher pathologic complete remission rate in ERBB2 (HER2)-receptor positive breast cancer patients with PIK3CA wild-type compared to those harboring a PIK3CA mutation (PMID: 26245675).||26245675|
|PIK3CA wild-type||breast cancer||no benefit||Dactolisib + WEHI-539||Preclinical - Cell culture||Actionable||In a preclinical study, inhibition of Pi3k signaling by BEZ235 did not sensitize PIK3CA wild-type breast cancer cell lines to WEHI-539 in culture (PMID: 27974663).||27974663|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03457896||Phase II||Cetuximab + Neratinib Neratinib + Trastuzumab||Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status||Active, not recruiting||USA||0|
|NCT01960023||Phase Ib/II||Cetuximab + Neratinib||Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer||Withdrawn||USA||0|